A $1.1 billion dollar deal was announced on December 1 for giant Johnson & Johnson to acquire breast implant and cosmetic specialities supplier, Mentor corporation.  Analysts say that recent market turmoil and the consumer spending slump may have forced the deal.  While breast implant procedures have dropped off significantly in the current market, non-invasive procedures like Botox have maintained strength. which could be good news for both companies.
By late 2010, Mentor (which will stand alone post-acquisition) is expected to receive FDA approval on a new wrinkle-relaxing, injectable neuroxtoxin called PurTox.  The product should place Mentor (and J&J) in direct competition with Botox manufacturer Allergan.
